Cipla Limited (CIPLA)
Investor Presentation
AI summary
- Q1FY27 consolidated revenue 7,119 Cr (+2.3% y-y); EBITDA 1,192 Cr (16.7% margin); PAT 789 Cr (11.1% margin)
- One India business steady with 15.4% market growth; chronic therapies show double-digit growth
- North America launched gVentolin; respiratory portfolio strong with gProventil #1 market share
- One Africa private business growing faster than market; 4 new launches in Q1FY27
- ESG progress: 57% renewable electricity share, 21% GHG reduction, water positivity 2.6x in India manufacturing
- Consolidated debt at 600 Cr; cash and equivalents 10,094 Cr as of June 2026
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 CIPLA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add CIPLA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Cipla Limited
Important.
The summary above is generated automatically from Cipla Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.